Determinants of Response to Antibiotic Therapy

REFERENCES

• Shann F. Pneumococcal vaccine: time for another controlled trial. Lancet 1998; 351: 1600–1601.
   PubMed Web of Science ®Google Scholar
• Hague K. Should intravenous immunoglobulins be used in the treatment of neonatal sepsis? Br J Intensive Care 1997; Jan/Feb: 12-13.
   Google Scholar
• Luzuriaga K, Bryson Y, Krogstad P, Robinson J, Stechenberg B, Lawson M. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997; 336: 1343-1349.
   Google Scholar
• Schneider CM, Daschner FD. Colony-stimulating factors and antibiotics - a new prospect in treating infectious diseases? Clin Microbiol Infect 1998; 4: 119–122.
   PubMedGoogle Scholar
• Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998; 351: 929–933.
   PubMed Web of Science ®Google Scholar
• Vincent J-L. Search for effective immunomodulating strategies against sepsis. Lancet 1998; 351: 922–923.
   PubMed Web of Science ®Google Scholar
• Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997; 24, 7: 1095–1100.
   Google Scholar
• Wenisch C, Parschalk B, Hasenhand M, Wiesinger E, Graninger W. Effect of cefodizime and ceftriaxone on phagocytic function in patients with severe infections. Antimicrob Agents Chemother 1995; 39: 672–676.
   PubMed Web of Science ®Google Scholar
• Patchen ML, Brook I, Elliott TB, Jackson WE. Adverse effects of pefloxacin in irradiated C3H/He N mice: correction with glucan therapy. Antimicrob Agents Chemother 1993; 37: 1882-1885.
   Google Scholar
• Labro MT. The prohost effect of antimicrobial agents as a predictor of clinical outcome. J Chemother 1997; 9 (suppl 1): 100-108.
   Google Scholar
• Bergogne-Berezin, E. Interactions among antibiotics, bacteria and the human immune system: the clinical relevance of in vitro testing. J Chemother 1997; 9 (suppl 1): 109-115.
   Google Scholar
• Den Hollander JG, Fuursted K, Verbrugh HA, Mouton JW. Duration and clinical relevance of postantibiotic effect in relation to the dosing interval. Antimicrob Agents Chemother 1998; 42: 749–754.
   PubMed Web of Science ®Google Scholar
• Jaffe A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998; 351: 420.
   PubMed Web of Science ®Google Scholar
• Casey LC. Antibiotics: more than just "bug" killers. Crit Care Med 1997; 8: 1270–1271.
   Google Scholar
• Galley HF, Nelson SJ, Dubbels AM, Webster NR. Effect of ciprofloxacin on the accumulation of interleukin-6, interleukin-8 and nitrite from a human endothelial cell model of sepsis. Crit Care Med 1997; 8: 1392-1395.
   Google Scholar
• Hartman G, Wise R. Quorum sensing: potential means of treating gram-negative infections? Lancet 1998; 351: 848–849.
   PubMed Web of Science ®Google Scholar
• Trautmann M, Zick R, Rukavina T, Cross AS, Marre R. Antibiotic-induced release of endotoxin: in-vitro comparison of meropenem and other antibiotics. J Antimicrob Chemother 1998; 41: 163–169.
   PubMed Web of Science ®Google Scholar
• Hurley JC. β-lactam antibiotic-induced release of free lipopolysaccharide. J Infect Dis 1993; 167: 775.
   PubMed Web of Science ®Google Scholar
• Jackson JJ. Reply. J Infect Dis 1993; 167: 775–776.
   PubMed Web of Science ®Google Scholar
• Arditi M, Kabat W, Yogev R. Antibiotic-induced bacteri-al killing stimulates tumor necrosis factor- release in whole blood. J Infect Dis 1993; 167: 240–244.
   PubMed Web of Science ®Google Scholar
• Lamp KC, Rybak MJ, McGrath B, Summers KK. Influence of antibiotic and E5 monoclonal immunoglobulin M interactions on endotoxin release from Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 247–252.
   PubMed Web of Science ®Google Scholar
• Nwariaku FE, McIntyre KL, Sikes PJ, Mileski WJ. The effect of antimicrobial agents on the induction of tumour necrosis factor by alveolar macrophages in vitro in response to endotoxin. J Antimicrob Chemother 1997; 39: 265–267.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Narita K, Kato Y, et al. Low level release of shiga like toxin (verocytotoxin) and endotoxin from entero-hemorrhagic Escherichia coli treated with imipenem. Antimicrob Agents Chemother 1997; 41: 2295–2296.
   PubMed Web of Science ®Google Scholar
• Kragsbjerg P, Soderquist B, Holmberg H, Vikerfors T, Danielsson D. Production of tumor necrosis factor- and inter-leukin-6 in whole blood stimulated by live Gram-negative and Gram-positive bacteria. Clin Microbiol Infect 1997; 4: 129–134.
   Google Scholar
• van Langevelde P, Kwappenberg KMC, Groeneveld PHP, Mattie H, van Dissel JT. Antibiotic-induced lipopolysac-charide (LPS) release from Salmonella typhi: delay between killing by ceftazidime and imipenem and release of LPS. Antimicrob Agents Chemother 1998; 42: 739–743.
   PubMed Web of Science ®Google Scholar
• Gould IM, MacKenzie FM. The response of Enterobacteriaceae to -lactam antibiotics - “round forms, filaments and the root of all evil”. J Antimicrob Chemother 1997; 40: 495–499.
   PubMed Web of Science ®Google Scholar
• Rekke O, Sveen G, Lehmann AK, Digranes A, Halstensen A. Endotoxin and cytokines in plasma and clinical manifestations during treatment of septicaemia with impenem or cefuroxime/metronidazole. Immunol Infect Dis 1996; 6: 159–166.
   Google Scholar
• Basoli A, Meli EZ, Mazzocchi P, Speranza V, & Study Group. Imipenem/cilastatin (1.5g daily) versus meropenem (3.0g daily) in patients with intra-abdominal infections: results of a prospective, randomoized, multicentre trial. Scand J Infect Dis 1997; 29: 503-508.
   Google Scholar
• Schneider CM, Huzly D, Vetter C, von Specht BU, Daschner FD. Tumor necrosis factor alpha and interleukin 6 release induced by antibiotic killing of Pseudomonas aeruginosa and Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1997; 16: 467–471.
   PubMed Web of Science ®Google Scholar
• Yokoshi T, Kusumi A, Kido N et al. Differential release of smooth-type lipopolysaccharide from Pseudomonas aerugi-nosa treated with carbapenem antibiotics and its relation to production of tumor necrosis factor alpha and nitric oxide. Antimicrob Agents Chemother 1996; 40: 2410–2412.
   Google Scholar
• Keil S, Wiedemann B. Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model. Antimicrob Agents Chemother 1997; 41: 1215–1219.
   PubMed Web of Science ®Google Scholar
• Fuchs PC, Stickel S, Anderson PH, Barry AL, Shilling S. In vitro inactivation of aminoglycosides by sulbactam, other beta-lactams, and sulbactan-beta-lactam combinations. Antimicrob Agents Chemother 1991; 35: 182–184.
   PubMed Web of Science ®Google Scholar
• Neilly IJ, Dawson AA, Golder DA, Gould IM. Absorption of ciprofloxacin after oral administration to leukaemic patients with presumed septicaemia. Antiinfect Drugs Chemother 1995; 13: 215–218.
   Google Scholar
• Cotterill S. Antimicrobial prescribing in patients on haemofiltration. J Antimicrob Chemother 1995; 36: 773–780.
   PubMed Web of Science ®Google Scholar
• Jones EM, McMullin CM, Hedges AJ, et al. The phar-macokinetics of intravenous ciprofloxacin 400mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. J Antimicrob Chemother 1997; 40: 121–124.
   PubMedGoogle Scholar
• Scaglione F, Demertini G, Arcidiacono MM, Dugnani S, Fraschini F. Influence of protein binding on the pharmacody-naimics of ceftazidime or ceftriaxone against Gram-positive and Gram-negative bacteria in an in vitro infection model. J Chemother 1998; 10: 29–34.
   PubMed Web of Science ®Google Scholar
• Dykhuizen RS, Harvey G, Stephenson N, Nathwani D, Gould IM. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother 1995; 39: 1842–1847.
   PubMed Web of Science ®Google Scholar
• Gould IM. Pharmacodynamics and the relationship between in vitro and in vivo activity of antimicrobial agents. J Chemother 1997; 9: 74–83.
   PubMed Web of Science ®Google Scholar
• Fuentes F, Izquierdo J, Martin MM, Gomez-Lus ML, Prieto J. Post antibiotic and sub-MIC effects of azithromycin and isepamicin against Staphylococcus aureus and Escherichia coli. Antimicrob Agents Chemother 1998; 42: 414–418.
   PubMed Web of Science ®Google Scholar
• Lutsar I, Ahmed A, Friedland IR, et al. Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1997; 41: 2414–2417.
   PubMed Web of Science ®Google Scholar
• Gould IM, Milne K, Harvey G, Jason AC. Ionic binding, adaptive resistance and post-antibiotic effect of netilmicin and ciprofloxacin. J Antimicrob Chemother 1991; 27: 741–748.
   PubMed Web of Science ®Google Scholar
• Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous cipro-floxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073–1081.
   PubMed Web of Science ®Google Scholar
• Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40: 45–57.
   PubMed Web of Science ®Google Scholar
• MacGowan AP, Bowker KE. Pharmacodynamics of antimicrobial agents and rationale for their dosing. J Chemother 1997; 9: 64–73.
   PubMed Web of Science ®Google Scholar
• Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients dur-ing therapy. Antimicrob Agents Chemother 1998; 42: 521–527.
   PubMed Web of Science ®Google Scholar
• Craig WA, Gudmundsson S. The postantibiotic effect. In: Lorian V, ed. Antibiotics in Laboratory Medicine 3rd edn. Baltimore: Williams & Wilkins, 1991: 403–431.
   Google Scholar
• Craig W, Ebert S, Watanabe Y. Differences in time above MIC (T>MIC) required for efficacy of beta-lactams in animal infection models. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993 American Society for Microbiology, Washington, DC. 1993: Abstract 86 p 135.
   Google Scholar
• Eagle H, Fleischman R, Levy M. The effect of the interval between injections on therapeutic efficacy. N Engl J Med 1953; 248: 480–488.
   Web of Science ®Google Scholar
• Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacoki-netic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831–847.
   PubMed Web of Science ®Google Scholar
• Soriano F, Ponte C, Santamaria M, Jimenez-Arriero M. Relevance of the inoculum effect of antibiotics in the outcome by experimental infections caused by Escherichia coli. J Antimicrob Chemother 1990; 25: 621–627.
   PubMed Web of Science ®Google Scholar
• Kessler RE, Bies M, Buck RE et al. Comparison of a new cephalosporin, BMY 28142, with other broad spectrum β-lactam antibiotics. Antimicrob Agents Chemother 1985; 27: 207–216.
   PubMed Web of Science ®Google Scholar
• Hobson RP, Gould IM. Aminoglycoside resistance. Antiinfect Drugs Chemother 1995; 13: 143–147.
   Google Scholar
• Sanders CC, Sanders WEJr. Clinical and epidemiologi-cal implications for use of newer cephalosporins. Rev Infect Dis 1988; 10: 830–836.
   PubMedGoogle Scholar
• MacKenzie FM, Gould IM. Extended spectrum β-lactamases- commentary. J Infect 1998; 36: 255–258.
   PubMed Web of Science ®Google Scholar
• Chadwick PR, Brown DEJ, Wilcox MH, et al. Comparison of agar-based media for primary isolation of gly-copeptide-resistant enterococci. Clin Microbiol Infect 1997; 3: 559–563.
   PubMedGoogle Scholar
• Paterson DL, Ko WC, Mohapatra S, et al. ESBL+ K. pneumoniae bacteraemia. 37th ICAAC 1997; Abstract no J210.
   Google Scholar
• Elhanan G, Sarhat M, Raz R. Empiric antibiotic treatment and the misuse of culture results and antibiotic sensitivi-ties in patients with community acquired bacteraemia due to urinary tract infection. J Infect 1997; 35: 283–288.
   PubMed Web of Science ®Google Scholar
• Ispahani P, Pearson NJ, Greenwood D. An analysis of community and hospital acquired bacteraemia in a large teach-ing hospital in the United Kingdom. Quart J Med 1987; 241: 427–440.
   Google Scholar
• Price J, Ekleberyy A, Johnson M, Melendy S, Villaba M, Zervos MJ. Evaluation of clinical practice guidelines on infection outcome and antibiotic resistance in an Intensive Care Unit. 37th ICAAC 1997; Abstract no J131.
   Google Scholar
• Cunney RJ, McNamara EB, Alansari N, Loo B, Smyth EC. The impact of blood culture reporting and clinical liaison on the empiric treatment of bacteraemia. J Clin Pathol 1997; 50: 1010–1012.
   PubMed Web of Science ®Google Scholar
• Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial resistant microorganisms in hospitals. J Am Med Assoc 1996; 275: 234–240.
   PubMed Web of Science ®Google Scholar
• Shackley P, Cairns J, Gould IM. Accelerated bacterio-logical evaluation in the management of lower respiratory tract infection in general practice. J Antimicrob Chemother 1997; 39: 663–666.
   PubMed Web of Science ®Google Scholar